LDLR and hyperlipidemia: Next are patients with mixed hyperlipidemia and high TG with high remnant exposure, in whom residual event risk arises more from TRLs and remnant cholesterol, a pathway less affected by conventional LDLR-directed drugs; ANGPTL3 inhibition offers upstream “debulking” and accelerated remnant clearance tailored to this profile (103).